Pyrilamine
Prefrin-a (pyrilamine) is a small molecule pharmaceutical. Pyrilamine was first approved as Prefrin-a on 1982-01-01. It is used to treat allergic conjunctivitis, allergic rhinitis perennial, allergic rhinitis seasonal, and pruritus in the USA. The pharmaceutical is active against histamine H1 receptor. In addition, it is known to target histamine H4 receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| acetaminophen 500mg caffeine 60mg pyrilamine maleate 15mg | OTC monograph not final | 2023-07-22 |
| acetaminophen,caffeine and pyrilamine maleate | OTC monograph not final | 2023-01-05 |
| broncochem | C200263 | 2024-04-22 |
| buscapina | C200263 | 2024-05-17 |
| capron dm | OTC monograph final | 2023-01-10 |
| capron dmt | unapproved drug other | 2024-01-30 |
| childrens pediaclear 8 | C200263 | 2024-10-07 |
| comfort-time | OTC monograph not final | 2018-12-14 |
| cramp tabs | C200263 | 2024-10-04 |
| curahist dm | C200263 | 2024-04-04 |
Show 34 more
Indications
FDA
EMA
Show 2 more
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
D: Dermatologicals
— D04: Antipruritics, incl. antihistamines, anesthetics, etc.
— D04A: Antipruritics, incl. antihistamines, anesthetics, etc.
— D04AA: Antihistamines for topical use
— D04AA02: Mepyramine
R: Respiratory system drugs
— R03: Drugs for obstructive airway diseases
— R03D: Other systemic drugs for obstructive airway diseases in atc
— R03DA: Xanthines, systemic for obstructive airway disease
— R03DA12: Mepyramine theophyllinacetate
— R06: Antihistamines for systemic use
— R06A: Antihistamines for systemic use
— R06AC: Substituted ethylene diamines, systemic antihistamines
— R06AC01: Mepyramine
HCPCS
No data
Clinical
Clinical Trials
583 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 125 | 1 | — | 1 | 6 | 132 |
| Hypotension | D007022 | EFO_0005251 | I95 | 3 | 6 | 4 | 17 | 21 | 49 |
| Asthma | D001249 | EFO_0000270 | J45 | 15 | 7 | 2 | 1 | 1 | 26 |
| Rhinitis | D012220 | EFO_0008521 | J31 | 3 | 6 | 3 | 4 | 4 | 20 |
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | 8 | 6 | 3 | 1 | 1 | 19 |
| Allergic rhinitis | D065631 | — | J30.9 | 2 | 6 | 3 | 4 | 2 | 17 |
| Mydriasis | D015878 | HP_0011499 | H57.04 | 2 | 1 | 5 | 6 | 3 | 17 |
| Anesthesia | D000758 | — | — | — | 2 | 4 | 3 | 5 | 14 |
| Spinal anesthesia | D000775 | — | — | — | 2 | 1 | 6 | 3 | 12 |
| Common cold | D003139 | EFO_0007214 | J00 | 2 | 1 | 6 | 1 | — | 10 |
Show 67 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Syndrome | D013577 | — | — | — | — | 2 | — | 6 | 8 |
| Obstructive lung diseases | D008173 | HP_0006536 | — | 2 | — | 2 | — | 1 | 5 |
| Respiratory tract infections | D012141 | — | J06.9 | 1 | — | 4 | — | — | 5 |
| Heart failure | D006333 | HP_0001635 | I50 | 2 | — | 1 | — | 2 | 5 |
| Cold temperature | D003080 | — | — | — | — | 3 | — | — | 3 |
| Cognitive dysfunction | D060825 | HP_0001268 | G31.84 | — | 2 | 1 | — | 1 | 3 |
| Infections | D007239 | EFO_0000544 | — | — | — | 3 | — | — | 3 |
| Nasal obstruction | D015508 | HP_0001742 | — | 1 | — | 2 | — | — | 3 |
| Intraocular lens implantation | D019654 | — | — | — | — | 3 | — | — | 3 |
| Fecal incontinence | D005242 | — | R15 | 2 | 1 | 1 | — | — | 3 |
Show 31 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Parkinson disease | D010300 | EFO_0002508 | G20 | 6 | 2 | — | — | 1 | 9 |
| Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | 3 | 1 | — | — | — | 4 |
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | 1 | 1 | — | — | 1 | 3 |
| Disease | D004194 | EFO_0000408 | R69 | 2 | 1 | — | — | — | 3 |
| Periodontitis | D010518 | EFO_0000649 | K05.3 | — | 3 | — | — | — | 3 |
| Dental caries | D003731 | EFO_0003819 | K02 | — | 3 | — | — | — | 3 |
| Periapical periodontitis | D010485 | EFO_1001391 | K04.5 | — | 3 | — | — | — | 3 |
| Wounds and injuries | D014947 | — | T14.8 | 1 | 2 | — | — | 1 | 3 |
| Hypertriglyceridemia | D015228 | EFO_0004211 | — | 1 | 1 | — | — | — | 2 |
| Vasovagal syncope | D019462 | — | R55 | 1 | 1 | — | — | — | 2 |
Show 27 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Vasoconstriction | D014661 | — | — | 5 | — | — | — | 5 | 10 |
| Therapeutic equivalency | D013810 | — | — | 9 | — | — | — | — | 9 |
| Cardiovascular diseases | D002318 | HP_0001626 | — | 3 | — | — | — | 5 | 8 |
| Pharmacokinetics | D010599 | — | — | 6 | — | — | — | — | 6 |
| Vasodilation | D014664 | — | — | 3 | — | — | — | 3 | 6 |
| Respiratory aspiration | D053120 | EFO_1001839 | — | 3 | — | — | — | 2 | 5 |
| Hypoxia | D000860 | HP_0012418 | R09.02 | 1 | — | — | — | 4 | 5 |
| Pain | D010146 | EFO_0003843 | R52 | 4 | — | — | — | — | 4 |
| Biological availability | D001682 | — | — | 4 | — | — | — | — | 4 |
| Essential hypertension | D000075222 | — | I10 | 3 | — | — | — | — | 3 |
Show 63 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pre-eclampsia | D011225 | EFO_0000668 | O14 | — | — | — | — | 5 | 5 |
| Carotid endarterectomy | D016894 | — | — | — | — | — | — | 3 | 3 |
| Aging | D000375 | GO_0007568 | R41.81 | — | — | — | — | 2 | 2 |
| Acute kidney injury | D058186 | HP_0001919 | N17 | — | — | — | — | 2 | 2 |
| Bone fractures | D050723 | EFO_0003931 | T14.8 | — | — | — | — | 2 | 2 |
| Femoral fractures | D005264 | — | S72 | — | — | — | — | 2 | 2 |
| Sinusitis | D012852 | EFO_0007486 | J32 | — | — | — | — | 2 | 2 |
| Respiratory insufficiency | D012131 | HP_0002093 | J96.9 | — | — | — | — | 2 | 2 |
| Deglutition disorders | D003680 | HP_0002015 | R13.1 | — | — | — | — | 2 | 2 |
| Neck pain | D019547 | HP_0030833 | M54.2 | — | — | — | — | 2 | 2 |
Show 97 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Pyrilamine |
| INN | mepyramine |
| Description | Mepyramine is an ethylenediamine derivative that is ethylenediamine in which one of the amino nitrogens is substituted by two methyl groups and the remaining amino nitrogen is substituted by a 4-methoxybenzyl and a pyridin-2-yl group. It has a role as a H1-receptor antagonist. It is an ethylenediamine derivative and an aromatic ether. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | COc1ccc(CN(CCN(C)C)c2ccccn2)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 91-84-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL511 |
| ChEBI ID | 6762 |
| PubChem CID | 4992 |
| DrugBank | DB06691 |
| UNII ID | HPE317O9TL (ChemIDplus, GSRS) |
Target
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Pyrilamine
+
Carbetapentane
+
Phenylephrine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Pyrilamine
+
Carbetapentane
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Pyrilamine
+
Chlophedianol
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Pyrilamine
+
Phenylephrine
+
Chlorpheniramine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Pyrilamine
+
Dextromethorphan
+
Phenylephrine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Pyrilamine
+
Dextromethorphan
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Pyrilamine
+
Phenylephrine
+
Hydrocodone
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Pyrilamine
+
Phenylephrine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 3,079 documents
View more details
Safety
Black-box Warning
Black-box warning for: Acetaminophen,caffeine and pyrilamine maleate
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
201 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use